ClinicalTrials.gg

Program

HSK39297

A development code. Also written as “HSK39297 tablets”, “HSK39297 200mgQD” and “HSK39297 300mgQD”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA · Lupus Nephritis, led by Haisco Pharmaceutical Group.

Furthest: phase 3, since Jan 23, 202510 company-led studies, 5 open or runningNext primary completion: Dec 5, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group105 open or runningphase 3since Jan 23, 2025Apr 1, 2024Dec 5, 2026phase 2 · NCT07616700

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 1, 2024First study: phase 1 study in HealthyFirst studyNCT06350279 · 96 enrolled · China
  2. Aug 16, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06561841 · 47 enrolled · China
  3. Oct 15, 2024Phase 2 study in Glomerulonephritis, IGANCT06670352 · 87 enrolled · China
  4. Dec 12, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06745622 · 47 planned · China
  5. Jan 23, 2025Phase 3 study in PNHNCT06799546 · 73 enrolled · China
  6. Jun 29, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT07052838 · 36 enrolled · China
  7. Aug 26, 2025Phase 1 study in Hemoglobinuria, ParoxysmalNCT07152288 · 24 planned · China
  8. Dec 3, 2025Phase 2 study in Lupus NephritisNCT07363460 · 105 planned · China
  9. Jan 29, 2026Phase 3 study in Glomerulonephritis, IGANCT07390123 · 370 planned · China
  10. Apr 7, 2026Phase 2 study in Glomerulonephritis, IGANCT07616700 · 73 planned · China

Ahead

  1. Dec 5, 2026Primary completion: phase 2 study in Glomerulonephritis, IGANCT07616700
  2. Jun 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06745622
  3. Nov 5, 2027Primary completion: phase 2 study in Lupus NephritisNCT07363460
  4. Dec 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT07390123

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07616700Glomerulonephritis, IGA · China2RecruitingDec 5, 202673
NCT07390123Glomerulonephritis, IGA · China3RecruitingDec 2027370
NCT07363460Lupus Nephritis · China2RecruitingNov 5, 2027105
NCT07152288Hemoglobinuria, Paroxysmal · China1RecruitingSep 202524
NCT07052838Hemoglobinuria, Paroxysmal · China3CompletedDec 23, 202536
NCT06799546PNH · China3CompletedNov 5, 202573
NCT06745622Hemoglobinuria, Paroxysmal · China2RecruitingJun 202747
NCT06670352Glomerulonephritis, IGA · China2CompletedDec 20, 202587
NCT06561841Hemoglobinuria, Paroxysmal · China2CompletedApr 2, 202547
NCT06350279Healthy · China1CompletedAug 2, 202496

How it is read

Names in the registry

  • “HSK39297 tablets”, 6 entries
  • “HSK39297 200mgQD”, 3 entries
  • “HSK39297”, 3 entries
  • “HSK39297 300mgQD”, 2 entries
  • “HSK39297 50mgBID”, 1 entry

Codes read as this program: HSK39297.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.